A Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of LNS8801 in Patients With Advanced Cancer

Conditions

Phase I

Volunteers
Health Professionals

What is the purpose of this trial?

LNS-101 is a multi-center study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of LNS8801 in patients with advanced cancer. This Phase 1, first-in-human, open-label, multi-center study is designed to determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D). LNS8801 will be administered until disease progression or unacceptable toxicity.

Find out more about who can participate in this trial

Trial with
Linnaeus Therapeutics, Inc.
Start Date
02/27/2020
End Date
10/29/2021

For more information about this study, contact:

Ingrid Palma

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Patricia LoRusso, DO
Professor of Medicine (Medical Oncology); Professor of Medicine; Associate Cancer Center Director, Experimental Therapeutics

Sub-Investigators

Last Updated
08/13/2020
Study HIC
#2000026326

A Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of LNS8801 in Patients With Advanced Cancer

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigators

Contact Information